| Literature DB >> 35523139 |
Pablo Hernández-Malmierca1, Dominik Vonficht1, Alexandra Schnell2, Hannah J Uckelmann3, Alina Bollhagen4, Mohamed A A Mahmoud4, Sophie-Luise Landua4, Elise van der Salm4, Christine L Trautmann4, Simon Raffel5, Florian Grünschläger1, Raphael Lutz6, Michael Ghosh7, Simon Renders6, Nádia Correia4, Elisa Donato4, Karin O Dixon2, Christoph Hirche8, Carolin Andresen1, Claudia Robens4, Paula S Werner8, Tobias Boch9, David Eisel10, Wolfram Osen10, Franziska Pilz8, Adriana Przybylla4, Corinna Klein4, Frank Buchholz11, Michael D Milsom12, Marieke A G Essers8, Stefan B Eichmüller10, Wolf-Karsten Hofmann13, Daniel Nowak13, Daniel Hübschmann14, Michael Hundemer5, Christian Thiede15, Lars Bullinger16, Carsten Müller-Tidow17, Scott A Armstrong3, Andreas Trumpp18, Vijay K Kuchroo19, Simon Haas20.
Abstract
Hematopoietic stem and progenitor cells (HSPCs) are responsible for the production of blood and immune cells. Throughout life, HSPCs acquire oncogenic aberrations that can cause hematological cancers. Although molecular programs maintaining stem cell integrity have been identified, safety mechanisms eliminating malignant HSPCs from the stem cell pool remain poorly characterized. Here, we show that HSPCs constitutively present antigens via major histocompatibility complex class II. The presentation of immunogenic antigens, as occurring during malignant transformation, triggers bidirectional interactions between HSPCs and antigen-specific CD4+ T cells, causing stem cell proliferation, differentiation, and specific exhaustion of aberrant HSPCs. This immunosurveillance mechanism effectively eliminates transformed HSPCs from the hematopoietic system, thereby preventing leukemia onset. Together, our data reveal a bidirectional interaction between HSPCs and CD4+ T cells, demonstrating that HSPCs are not only passive receivers of immunological signals but also actively engage in adaptive immune responses to safeguard the integrity of the stem cell pool.Entities:
Keywords: CD4(+) T cells; acute myeloid leukemia; antigen presentation; hematopoietic stem cells; immune regulation; immunosurveillance; leukemia
Mesh:
Year: 2022 PMID: 35523139 PMCID: PMC9202612 DOI: 10.1016/j.stem.2022.04.007
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 25.269